Drug Trial Radar · NCT05324293
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 11, 2022
Primary completion
Sep 11, 2023
Study completion Sep 11, 2023
Sponsor
- Lead sponsor
- Hope Medicine (Nanjing) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
Conditions
- Androgenetic Alopecia
Interventions
HMI-115Drug
Once Every 2 weeks, subcutaneously injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- TAHC(target area hair count) of non-vellusTime frame: From baseline to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr Rodney Sinclair Pty Ltd, trading as Sinclair Dermatology
Melbourne E., Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.